Secondary Hyperparathyroidism Treatment (SHPT) Market |2021 Analysis, Key Opportunities Major Players, Impact of COVID-19 and Size, Growth, Share, Regional Analysis With Global Industry Forecast To 2027, The increasing launch of effective drugs is a key factor driving the “U.S. Secondary Hyperparathyroidism Treatment Market” Size says Fortune Business Insights in a report, titled “Secondary Hyperparathyroidism Treatment (SHPT) Market” ,Size, Share Industry Analysis, By Drug Class (Calcimimetics, Vitamin D Analogues, and Phosphate Binders), By Distribution Channel (Hospital Retail Pharmacies, Online Channels, and Others) and Region Forecast, 2019-2026.” The secondary hyperparathyroidism treatment (SHPT) market was valued at USD 4.34 Billion in 2018 and is expected to reach USD 7.06 Billion by 2026, exhibiting a CAGR of 9.0%. As per the report the secondary hyperparathyroidism treatment market on the basis of drug class is segmented into calcimimetics, vitamin d analogues, and phosphate binders.

The calcimimetics segment is expected to hold maximum share during the forecast period owing to the numerous generic substitutes of Cinacalcet in the U.S. along with the rising demand for potent and specific therapy for the treatment of SHPT. For instance, according to a national survey conducted by American Journal of Kidney Diseases the use of Cinacalcet has increased from 23% to 31% between 2014 and 2017

The report provides a comprehensive assessment of the secondary hyperparathyroidism treatment market by inculcating valuable insights, facts, industry-related information, and historical data. Numerous approaches and methods are implemented to make meaningful assumptions and views. Furthermore, it offers a detailed analysis and information as per market segments, helping readers to get an inclusive overview of the market.

Request a Sample Copy of the Research Report: 

https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/u-s-secondary-hyperparathyroidism-shpt-treatment-market-101664

Rising Prevalence Of Chronic Kidney Disease Will Stimulate Growth

The increasing prevalence of chronic kidney disease among geriatric population as well as general population will enable the growth of the secondary hyperparathyroidism treatment market during the forecast period. According to the Centers for Disease Control and Prevention (CDC), around 15% of U.S adults, which, is, 37 million people are estimated to have chronic kidney disease. Additionally, CKD is found more common in people aged 65 years or older than in people aged 45-64 years. The rising cases of renal disease and increasing patient pool will have a significant impact on the market.  The increasing cost burden for the treatment of secondary hyperparathyroidism will further encourage growth of the market. In addition, the launch of generic form of Cinacalcet hydrochloride tablets will bode well for the secondary hyperparathyroidism treatment market. For instance, Cipla Inc. and its subsidiary Cipla USA Inc. announced the launch of a generic form of Cinacalcet hydrochloride tablets in USA. Moreover, Amgen Inc. announced the USFDA approval of Parsabiv for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease (CKD). The approval for Parsabiv will also aid the growth of the market during the forecast period.

What does the Report Include?

The market report includes quantitative and qualitative analysis of several factors such as the key drivers and restraints that will impact growth. Additionally, the report provides insights into the regional analysis that covers the different regions, which are contributing to the growth of the market. It includes the competitive landscape that involves leading companies and adoption of strategies by them to introduce new products, announce partnerships, and collaboration that will contribute to the growth of the market between 2020 and 2027. Moreover, the research analyst has adopted several research methodologies such as PESTEL and SWOT analysis to extract information about the current trends and industry developments that will drive the market growth in the forthcoming years.

Secondary Hyperparathyroidism Treatment (SHPT) Highlights of the Report:

1. Market Penetration: Comprehensive information on the product portfolios of the top players in the market.
2. Product Development/Innovation: Detailed insights on the upcoming technologies, RandD activities, and product launches in the market
3. Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market
4. Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies
5. Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the market

Please Visit: https://www.fortunebusinessinsights.com/industry-reports/u-s-secondary-hyperparathyroidism-shpt-treatment-market-101664

Leading Players operating in the U.S Secondary Hyperparathyroidism Treatment Market are:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Genzyme Corporation (Sanofi)
• AbbVie Inc.
• Cipla Inc.
• Reddy’s Laboratories Ltd.
• OPKO Health, Inc.
• Other Prominent Players